Our team at Neogap consists of highly skilled and motivated professionals from diverse backgrounds, including academia and the pharmaceutical industry. With extensive experience and a track record of success, we are committed to advancing the field of cancer immunotherapy. We work together to develop innovative solutions that are at the forefront of cancer research, with a focus on personalised immunotherapy to combat cancer.
CEO
PhD, Prof Linköping University
Samuel brings over 25 years of experience in pharmaceutical development to Neogap. He has served as Head of Department and Project Leader at AstraZeneca R&D, where he successfully took three substances from development into phase I clinical trials. Samuel is also a Co-founder of Alzecure Foundation and serves as a Board Member for Biopercept Ltd, Celluminova, and Oxiant Discovery.
In addition to his industry experience, Samuel is an Adjunct Professor of Pharmacology and Chemistry at Linköping University, where he contributes to the education and training of the next generation of scientists.
COO
MSc Engineering
Andrea is a highly experienced professional in the biopharmaceutical industry. She has a background in process development and manufacturing of biologics for clinical trials, and more recently she has also gained in depth experience from clinical trial management. Her career has included roles as a Project Manager at CDMO Cobra Biologics, as well as positions at AstraZeneca, Recipharm, and Scandinavian Development Services.
CTO
PhD, Assoc Prof Karolinska Institutet
With a career spanning over 25 years, Guro is a renowned expert in immunological research, particularly in the area of T cells. She has conducted research at Karolinska Institutet and served as the former Director of Immunology at Viscogel, where she managed an EU project that included a phase I/II clinical trial. Guro is also an Associate Professor of Molecular Immunology at Karolinska Institutet.
CSO and founder
PhD, Assoc Prof Karolinska Institutet
With over 30 years in academic research and the pharmaceutical industry, Hans is a experienced expert in the field. He has previously served as Director of the Reagents Department at Pharmacia Diagnostics and founded Medi-Tec R&D. Hans is also an Associate Professor of Immunology and Research Group Leader at the Department of Clinical Neuroscience at Karolinska Institutet.
Acting CFO
MSc
Lars-Erik has over 20 years of experience from senior positions at biotech and pharmaceutical start-ups, including Moberg Pharma, Viscogel AB, and Medi-Tec Research & Development Stockholm AB. He has previously also served as Regional Business Controller for Latin America at Oriflame Cosmetics.
Consulting Medical Director
MD, PhD, Assoc Prof
Per is a seasoned clinical pharmacology specialist with deep expertise in oncology drug development and strategic business partnerships. His career is distinguished by successfully bridging scientific innovation and pharmaceutical commercialisation, particularly in facilitating collaborative agreements between biotechnology companies and major pharmaceutical corporations.
Principal Scientist Clinical Development
MD, PhD
Sofia manages the translational aspects of the Neogap pipeline and links the pTTL product development team and the clinical team together. Much of her work is focused on clinical trial design and trial administration. Her background with a combination of clinical experience as a medical doctor and a PhD in preclinical T cell and adoptive cell therapy research provides her with a comprehensive understanding of both worlds.
Head of Cell Therapy Production, Development and Analysis
BSc
Kristine has over 25 years of combined academic, hospital, GLP and GMP laboratory experience in the US and Europe. This includes the Medical College of Wisconsin (Wisconsin, USA), Novartis & the Friedrich Miescher Institute (Basel, Switzerland), Karolinska Institute, Astrazeneca and Procella Therapeutics (Sweden). Kristine’s experience in developing an allogenic ATMP product, encompassing GLP toxicology studies and GMP manufacturing preparations, has equipped her well for her role at Neogap.
Head of Neoantigen Production, Development and Clinical Processing
MSc, PhD
Ola leads the team for production and development of neoantigens, which are key components in Neogap’s personalised cancer therapies. The team also focuses on the processing of clinical study samples from patients enrolled in Neogap’s ongoing clinical study. He has extensive experience from clinical production, software, and process development, and is a merited scientist with background in immunology, biochemistry, bioinformatics and oncology.
Head of Quality Assurance and Quality Control
MSc Engineering, PhD
Andreas has over 20 years of experience in the biotech field, with a strong industrial background including roles at Lingvitae, Attana, and Biosensor Applications. At Neogap, he has established and manages the quality management system, ensuring regulatory compliance in manufacturing and clinical trial sample analysis. His expertise spans various areas, including quality management, regulatory compliance, and process development in biotechnology.
Scientific Lead for Cell Therapy Development and Analysis
MSc, PhD
As Scientific Lead for Neogap’s cell therapy development, Anne-Laure is responsible for cell product development and transfer to GMP-compliant production. Anne-Laure is an experienced research scientist in molecular and cellular immunology with an emphasis on immunological tolerance. Anne-Laure’s dual interest in fundamental and clinical research makes her role pivotal to future applications.
Chairman of the board
MD, PhD
Johan is an accomplished drug discovery and development leader with a proven track record of delivering candidate drugs and achieving clinical proof of concepts. He has held VP positions at AstraZeneca, Pfizer, and Celgene, and is currently the CEO and co-founder of Neuventis Therapeutics, co-founder of Mesenkia Therapeutics, founder of MBS Pharma and CSO of Aqilion. Johan also serves on the board of Pelago Bioscience.
MSc Engineering
Anna is the founder and CEO of Complyit, a leading life science consulting company that she has developed from a start-up to a profitable business with over 100 consultants. Prior to this, she served as the VP QA and Validation at Pharmadule and worked as a Quality Engineer at AstraZeneca. She brings extensive experience in corporate governance and regulatory compliance within pharmaceuticals, biotechnology, and medical technology.
MBA
Steve has extensive experience in business development, commercialisation, and biotechnological applications, including DNA sequencing in oncology. He has a vast international network of contacts in the field, which he has built through his work as the Owner of CG Biology, Vice President & General Manager at Celsee, Inc., Sales Executive at 10X Genomics, Clinical Account Manager at Thermo Fisher Scientific, and Head of NGS at the Swedish Institute for Communicable Disease Control.
CTO
PhD, Assoc Prof
With a career spanning over 25 years, Guro is a renowned expert in immunological research, particularly in the area of T cells. She has conducted research at Karolinska Institutet and served as the former Director of Immunology at Viscogel, where she managed an EU project that included a phase I/IIa clinical trial. Guro is also an Associate Professor of Molecular Immunology at Karolinska Institutet.
Acting CFO
MSc
Lars-Erik has over 20 years of experience from senior positions at biotech and pharmaceutical start-ups, including Moberg Pharma, Viscogel AB, and Medi-Tec Research & Development Stockholm AB. He has previously also served as Regional Business Controller for Latin America at Oriflame Cosmetics.
